Navigation Links
Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages
Date:3/9/2009

MOUNTAIN VIEW, Calif., March 9 /PRNewswire/ -- Based on its recent analysis of the prosthetic heart valves market, Frost & Sullivan recognizes ValveXchange, Inc. with the 2009 North American Frost & Sullivan Technology Innovation of the Year Award for developing the innovative ValveXchange Heart Valve System. Based on a two-part bioprosthetic tissue valve, the patented system promises to mitigate the compromises between traditional mechanical and tissue heart valves while providing maximal patient benefits.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Globally, 95 percent of all valve replacements are for aortic or mitral valves and require major surgery, which in some cases is associated with inflammation and ultimately prolong recuperation time. Of the two options - tissue or mechanical replacement valves - available to patients, tissue valves remain the preferred option. These originate from animal tissue and closely resemble the patient's original valve, and do not require long-term anticoagulation therapy with its inherent lifestyle impact. However, these bioprosthetic valves themselves may require a replacement within the patient's lifetime. To replace the worn-out valve, the patient undergoes the same invasive procedure as before (opening the chest and putting the patient on the cardiopulmonary bypass pump for the second time). This can lead to significant risk and trauma for the patient, and therefore these valves have been primarily used for the geriatric population. More durable, longer-lasting mechanical valves have traditionally been used for younger patients, but they carry an increased risk for blood clotting, which necessitates lifelong anticoagulation therapy with significant lifestyle adjustments. The ValveXchange approach offers the benefits of tissue valve technology to both younger and older patients.


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Frost & Sullivan: Ageing Population and Availability of Preventative Medicines Propels Growth of European Eye Health Ingredients Market
2. According to Frost & Sullivan, Mounting Clinical Evidence Underlines Benefits of Bone Growth and Spinal Fusion Stimulators
3. Frost & Sullivan Lauds OVATION Pharmaceuticals for Its Business Model and Ability to Sustain Growth
4. Frost & Sullivan Lauds Aesku.Diagnostics For Providing an Overall Analysis Platform For a Wide Range of Autoimmune Complications
5. Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System
6. Frost & Sullivan Says, Rising Awareness Boosts High Acuity Areas Monitoring Systems Market in Eastern Europe
7. Frost & Sullivan Awards to Celebrate Healthcare Excellence
8. Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan
9. Frost & Sullivan: The Brazilian Municipal Water and Wastewater Treatment Market Set to Double Within the Next Seven Years
10. Frost & Sullivan: Novel Diagnostics Methods Driving the European Cancer IVD Market Towards Early Detection and Prevention
11. Frost & Sullivan Recognizes WCC for Its Unique Multimodal Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... the groundwork for their own spread throughout the body ... tumor-welcoming signals, according to a new report by Johns ... of Nature Communications , the researchers describe animal ... signaling molecules released by breast cancer cells. These molecules ... lymph nodes to produce proteins called CCL5 and VEGF. ...
(Date:9/2/2014)... Kathleen Doheny HealthDay Reporter ... U.S. obesity epidemic is a driving force behind the rising ... Researchers looked at data from five national surveys spanning ... in diabetes over time could be explained by factors such ... adults. The investigators found that the prevalence of diabetes ...
(Date:9/2/2014)... -- A leading group of oncologists has released updated ... advanced breast cancer. HER2-negative breast tumors include ... HER2 protein, the American Society of Clinical Oncology (ASCO) ... 80 percent of women with advanced breast cancer have ... guideline, our aim is to improve both the length ...
(Date:9/2/2014)... latest research on sleep apnea, tonsillectomies, hearing loss, ... will be presented in Orlando, FL, September 21-24, ... of the American Academy of OtolaryngologyHead and Neck ... ear, nose, throat, head and neck physicians in ... be presented were released today, and are available ...
(Date:9/2/2014)... September 02, 2014 The first ... Pinnacle hip implant ( http://www.depuypinnacle-lawsuit.com/depuy-pinnacle-hip-implant/ ) will soon ... the U.S. District Court, Northern District of Texas, ... Johnson & Johnson and its DePuy Orthopaedics unit ... all-metal hip caused recipients to suffer serious and ...
Breaking Medicine News(10 mins):Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4
... leverage Risk MonitorPro, (R) and Feedback ... patient feedback and adverse events,CAMBRIDGE, MA, Jan. 13 ... quality and safety software, announced today that Woman,s Hospital ... and quality of care initiatives. , Named by Modern ...
... Straight Wire Seminars(TM) Celebrates 3 Decades of Orthodontic ... Straight Wire Seminars , Inc., a leading provider ... 30th anniversary starting this month, January 2009. ... milestone by offering a wide array of courses ...
... to enter Animal Health Rapid Diagnostics Market with a ... 13 Abaxis, Inc. (Nasdaq: ABAX ), ... for both the medical and veterinary markets, announced today ... for the manufacturing of a Canine Heartworm Lateral Flow ...
... Merck Serono and Apitope to Collaborate on Development ... the Treatment of Multiple Sclerosis (MS)GENEVA, Jan. 13 ... Darmstadt, Germany, announced today the signature of a ... (Bristol) Ltd., a wholly owned subsidiary of Apitope ...
... The National Eczema Association (NEA) awarded its Seal ... Theraplex Clear Lotion .The NEA Seal of Acceptance is ... program, which is intended to improve the quality of ... skin. "These products met our criteria for having no ...
... and Web 2.0 as Top Security Concerns and Steps Organizations Need to ... ... Ariz. (PRWEB) January 13, 2009 -- What will be the biggest threats ... 24 months? Cybercrime, data breaches , Web 2.0 and outsourcing were ...
Cached Medicine News:Health News:Woman's Hospital Selects rL Solutions for Improved Adverse Event and Patient Safety Reporting 2Health News:Don't Trust Any Continuing Education Provider Under 30 2Health News:Don't Trust Any Continuing Education Provider Under 30 3Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 2Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 3Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 2Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 3Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 4Health News:National Eczema Association Anoints Theraplex Products with Seal of Acceptance 2Health News:Lumension Security Webinar Focuses on Security Mega Trends and Emerging Threats in 2009 2Health News:Lumension Security Webinar Focuses on Security Mega Trends and Emerging Threats in 2009 3
(Date:9/2/2014)... 2, 2014    - ... muestran agentes antitrombóticos no utilizados óptimamente para prevenir ... Las presentaciones de GARFIELD-AF en el ESC CONGRESS ... los resultados de pacientes en riesgo de sufrir ... Los datos de casi 12.500 pacientes ...
(Date:9/2/2014)... 2, 2014 , ... provide insight into treatment and outcomes of patients ... --   Data from nearly 12,500 ... the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent academic ... for atrial fibrillation (AF) patients remain sub-optimal despite ...
(Date:9/2/2014)... -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... at the Morgan Stanley Global Healthcare Conference in ... September 9, 2014 , Presentation time: 5:15 p.m. ET ... of this presentation will be available at http://ir.avanir.com . ... Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... is the principal hormone responsible for the control ... the b-cells of the islets of Langerhans as ... C-peptide and insulin. Both are secreted in ... mature insulin molecule is comprised of two polypeptide ...
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane...
Medicine Products: